A new study links semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of hair loss, especially in ...

Student scientists have developed an incredible new way to synthesize drugs on plants — and they're using Ozempic as their ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

(HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among k ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

GLP-1RA discontinuation and lack of reinitiation was more common among patients with obesity and without type 2 diabetes than with type 2 diabetes.